Domain Lead Investigators
Domain Description
| Objective | The study aims to identify biologically and clinically distinct subphenotypes of AHRF in immunocompromised patients. It also evaluates key clinical outcomes such as short‑term and long‑term mortality within each subgroup, and explore whether early respiratory management strategies perform differently across these subphenotypes. Together, these objectives seek to advance precision medicine approaches for a population with high morbidity and limited targeted treatment options. |
|---|---|
| Population | The study includes adults aged 18 and older who are immunocompromised and meet criteria for AHRF either on non invasive respiratory support or invasive ventilation. Immunocompromise may be due to conditions such as long term corticosteroid use, recent immunosuppressive therapy, active cancer, solid organ transplant, or recent stem cell transplant. Patients receiving palliative care are excluded. |
| Primary Endpoint | The primary endpoint is the identification of meaningful subphenotypes of severe AHRF among immunocompromised patients. These subgroups will be defined using a combination of clinical characteristics, respiratory mechanics, and blood based biomarkers. |
| Design | The ESCAPE study is a prospective, multi‑centre observational cohort designed to better understand acute hypoxemic respiratory failure (AHRF) in immunocompromised adults. Because it is observational, no treatments are assigned; instead, the study collects detailed clinical information, respiratory data, and blood samples on days 0, 3, and 7. The goal is to enroll 500 patients over 2.5 years across multiple participating ICUs, allowing researchers to map patterns of illness and outcomes within this high‑risk population. |